cytarabine has been researched along with 1-arabinofuranosylcytosine-5'-stearylphosphate in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (8.33) | 18.7374 |
| 1990's | 10 (83.33) | 18.2507 |
| 2000's | 1 (8.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Deguchi, K; Kageyama, S; Komada, F; Minami, N; Morita, K; Nishikawa, M; Shirakawa, S; Uemura, Y | 1 |
| Higashigawa, M; Hori, H; Kawasaki, H; Ohkubo, T; Sakurai, M; Yoshizumi, T | 1 |
| Suga, T; Takayama, H; Watanabe, T; Yamada, J; Yoshida, Y | 1 |
| Arakawa, M; Ekimoto, H; Ishii, T; Kusama, K; Nagahata, T; Shibasaki, C; Takahashi, K; Uchida, T | 1 |
| Kodama, K; Kuninaka, A; Morozumi, M; Saitoh, K; Saneyoshi, M; Yoshino, H | 1 |
| Arie, Y; Hirai, M; Kikukawa, M; Kodo, H; Kumakawa, T; Mizutani, R; Mori, M; Murai, Y; Nakamura, N; Tsutsumi, H | 1 |
| Braess, J; Hiddemann, W; Kaufmann, C; Ramsauer, B; Schleyer, E; Schüssler, M; Unterhalt, M; Wilde, S | 1 |
| Niitsu, N; Shikoshi, K; Takada, M; Umeda, M | 1 |
| Tsukagoshi, S | 1 |
| Ito, T; Konishi, H; Maesako, Y; Mori, S; Ueda, Y; Yagiri, Y | 1 |
| Braess, J; Freund, M; Hanauske, A; Heil, G; Hiddemann, W; Kaufmann, C; Kern, W; Schleyer, E; Schüssler, M | 1 |
| Berger, U; Hehlmann, R; Hochhaus, A; Kuhn, C; Reiter, A | 1 |
2 review(s) available for cytarabine and 1-arabinofuranosylcytosine-5'-stearylphosphate
| Article | Year |
|---|---|
[Recent development of antitumor antimetabolites in Japan--cytosine arabinoside analogues].
Topics: Animals; Antimetabolites, Antineoplastic; Arabinonucleotides; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cytarabine; Cytidine Monophosphate; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Mice; Neoplasm Transplantation | 1997 |
AraC-based pharmacotherapy of chronic myeloid leukaemia.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleotides; Clinical Trials as Topic; Cytarabine; Cytidine Monophosphate; Drug Administration Schedule; Guidelines as Topic; Humans; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Survival Analysis | 2001 |
3 trial(s) available for cytarabine and 1-arabinofuranosylcytosine-5'-stearylphosphate
| Article | Year |
|---|---|
Pharmacokinetics of Ara-CMP-Stearate (YNK01): phase I study of the oral Ara-C derivative.
Topics: Administration, Oral; Antineoplastic Agents; Arabinofuranosyluracil; Arabinonucleotides; Cytarabine; Cytidine Monophosphate; Dose-Response Relationship, Drug; Half-Life; Humans; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Statistics, Nonparametric | 1995 |
[A pharmacokinetic study of the value of oral cytarabine ocfosfate in the treatment of hematological malignancies].
Topics: Administration, Oral; Aged; Antineoplastic Agents; Arabinonucleotides; Cytarabine; Cytidine Monophosphate; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Time Factors | 1998 |
Oral cytarabine ocfosfate in acute myeloid leukemia and non-Hodgkin's lymphoma--phase I/II studies and pharmacokinetics.
Topics: Acute Disease; Administration, Oral; Adult; Antineoplastic Agents; Arabinonucleotides; Biological Availability; Cytarabine; Cytidine Monophosphate; Diarrhea; Dose-Response Relationship, Drug; Half-Life; Humans; Infusions, Intravenous; Leukemia, Myeloid; Lymphoma, Non-Hodgkin; Metabolic Clearance Rate; Prodrugs; Regression Analysis | 1998 |
7 other study(ies) available for cytarabine and 1-arabinofuranosylcytosine-5'-stearylphosphate
| Article | Year |
|---|---|
[A case of complete remission from acute unclassified leukemia achieved by using a prodrug of ara C, stearyl-ara-CMP (YNK01)].
Topics: Acute Disease; Administration, Oral; Antineoplastic Agents; Arabinonucleotides; Cytarabine; Cytidine Monophosphate; Drug Administration Schedule; Female; Humans; Leukemia; Middle Aged; Prodrugs; Remission Induction | 1990 |
Deoxyribonucleoside triphosphate pools and Ara-CTP levels in P388 murine leukemic cells treated with 1-B-D-arabinofuranosylcytosine-5'-stearylphosphate which is a newly synthesized derivative of 1-B-D-arabinofuranosylcytosine.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Arabinonucleotides; Chromatography, High Pressure Liquid; Cytarabine; Cytidine Monophosphate; Deoxyribonucleotides; Leukemia P388; Male; Mice | 1990 |
Participation of the peroxisomal beta-oxidation system in the chain-shortening of PCA16, a metabolite of the cytosine arabinoside prodrug, YNKO1, in rat liver.
Topics: Animals; Arabinonucleotides; Cells, Cultured; Clofibrate; Coenzyme A Ligases; Cytarabine; Cytidine Monophosphate; Cytosine Nucleotides; Hydrogen Peroxide; Ketone Bodies; Liver; Microbodies; Mitochondria, Liver; Palmitates; Prodrugs; Rats; Rats, Inbred Strains; Repressor Proteins; Saccharomyces cerevisiae Proteins | 1990 |
[Antitumor activity of a novel analog of cytarabine, 4-amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone 5'-(sodium octadecyl phosphate) monohydrate (YNK01)].
Topics: Administration, Oral; Animals; Antineoplastic Agents; Arabinonucleotides; Cytarabine; Cytidine Monophosphate; Cytosine Nucleotides; Drug Administration Schedule; Drug Screening Assays, Antitumor; Female; Injections, Intraperitoneal; Injections, Intravenous; Leukemia L1210; Male; Mice; Neoplasms, Experimental; Tumor Cells, Cultured | 1990 |
Antitumor activity and pharmacology of 1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate: an orally active derivative of 1-beta-D-arabinofuranosylcytosine.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Arabinonucleotides; Cytarabine; Cytidine Monophosphate; Cytosine Nucleotides; Drug Administration Schedule; Leukemia L1210; Metabolic Clearance Rate; Mice; Solubility; Structure-Activity Relationship | 1989 |
[Plasma concentration of cytosine arabinoside (Ara-C) in the elderly patients with hematological malignancy treated by Ara-C or cytarabine ocfosfate (SPAC)].
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Arabinonucleotides; Cytarabine; Cytidine Monophosphate; Female; Humans; Infusions, Intravenous; Injections, Subcutaneous; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes | 1995 |
[Therapy-related acute non-lymphocytic leukemia (M2) with 7;11 chromosome translocation induced into complete remission by low dose cytosine arabinoside and cytarabine ocfosfate therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleotides; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 7; Cytarabine; Cytidine Monophosphate; Female; Humans; Leukemia, Myeloid, Acute; Neoplasms, Second Primary; Remission Induction; Translocation, Genetic | 1994 |